These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32557011)

  • 1. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
    Yu WL; Toh HS; Liao CT; Chang WT
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):205-214. PubMed ID: 32557011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
    Khezri MR; Zolbanin NM; Ghasemnejad-Berenji M; Jafari R
    Eur J Pharmacol; 2021 Aug; 905():174191. PubMed ID: 34015317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell responses and therapies against SARS-CoV-2 infection.
    Toor SM; Saleh R; Sasidharan Nair V; Taha RZ; Elkord E
    Immunology; 2021 Jan; 162(1):30-43. PubMed ID: 32935333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
    Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
    Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin in the treatment of COVID-19: a review.
    Echeverría-Esnal D; Martin-Ontiyuelo C; Navarrete-Rouco ME; De-Antonio Cuscó M; Ferrández O; Horcajada JP; Grau S
    Expert Rev Anti Infect Ther; 2021 Feb; 19(2):147-163. PubMed ID: 32853038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoronavirus and Immunomodulatory Phenolic Compounds: Opportunities and Pharmacotherapeutic Perspectives.
    Dejani NN; Elshabrawy HA; Bezerra Filho CDSM; de Sousa DP
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
    Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
    Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinacrine as a potential treatment for COVID-19 virus infection.
    Pineda B; Pérez de la Cruz V; Hernández Pando R; Sotelo J
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):556-566. PubMed ID: 33506949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.
    Yang Y; Cui X; Wei H; Guo C; Zhang Y
    Drug Des Devel Ther; 2021; 15():1213-1223. PubMed ID: 33762818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
    Perazzolo S; Zhu L; Lin W; Nguyen A; Ho RJY
    J Pharm Sci; 2021 Mar; 110(3):1002-1017. PubMed ID: 33248057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
    Zarandi PK; Zinatizadeh MR; Zinatizadeh M; Yousefi MH; Rezaei N
    Biomed Pharmacother; 2021 May; 137():111352. PubMed ID: 33550050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19.
    Bernini R; Velotti F
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
    Campos DMO; Fulco UL; de Oliveira CBS; Oliveira JIN
    J Evid Based Med; 2020 Nov; 13(4):255-260. PubMed ID: 33058394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.